Navigation Links
SPO Medical Reports 2007 Sales: Growth of 35% Compared to 2006
Date:3/25/2008

ur operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor Contacts

SPO Medical:

Michael Braunold, President & CEO

info@spomedical.com

+1-805-823-8163

Target 3 Communications:

Jerry Cahn, Ph.D., J.D., President

jerry@target3.com

+1-646-827-0009


'/>"/>
SOURCE SPO Medical equipment Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...en long-term side effects, study finds , ...otherapy alone, and delaying or avoiding radiation... with inoperable or progressive low-grade glioma b...udy. , Low-grade glioma is the most common brai...the survival rate for patients is 95 percent. But ...
(Date:10/10/2008)...cientists have identified a protein that plays mat..., T and B cells, enabling them to interact in a wa...unity after an infection. Their finding may also ...fect that prevents them from making this proteinca...n virus that otherwise is rarely fatal (Epstein-Ba...
(Date:10/10/2008)...ire-FirstCall/ -- Accuray,Incorporated (Nasdaq: A...y,today announced that it will report results for...ber 27, 2008, on Wednesday, October 29, 2008 after...the results will begin at 2:00 p.m. PDT,(5:00 p.m...., president and,chief executive officer and Holly ...
(Date:10/9/2008)...ive Accredited Course for,Non-Dermatologists about... November 1, 2008 at the Royal Sonesta Hotel Bosto...ire-USNewswire/ -- The Melanoma,Foundation of New ...ne are,co-sponsoring an Accreditation Council for ...ate non-dermatologists on the detection and manage...
Breaking Medicine News(10 mins):Health News:Chemo Alone Effective in Treating Kids' Brain Tumors 2Health News:NIH scientists discover crucial control in long-lasting immunity 2Health News:NIH scientists discover crucial control in long-lasting immunity 3Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2
...ealth Organisation experts visioned Australians ar...tries // . When addressing in National Medicines ...ustralia has got the best systems all over the wor...vative medicines. Dr Laing's words that triggers ...
...desparities among governments both state and feder...ed for mental health services need to be squandere...revious approaches it was clear that both were hav... The former competition regulator, Professor Hicki...
...k of a vine is thought to possess properties very ...f diabetics and the obese // . This discovery has ...an is the former federal health minister Michael W...s yet to apply for a patent, so your guess is as g...
...ng to the Royal College of GPs they plan to introd... Michelin-style rating system // . They are asking...e of grading but ministers and the British Medical...is the surgeries were to be inspected by doctors, ...
Other Medicine News:
(Date:10/8/2008)..., France, Oct. 8 /- Vical Incorporate...inical data and new nonclinical data,demonstrating...roadly,applicable in DNA- and protein-based infect...cines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,... present the data today,Wednesday, October 8, at ...
(Date:10/7/2008)...aluates the efficacy of new device for detecting p...ing colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswir...Annual Scientific Meeting in Orlando (ACG 2008), r...ented results from a,multi-institutional clinical ...(R) Retroscope(R), a new device that is designed t...
(Date:10/7/2008)...Showed Larazotide Acetate Prevented Immunologic Ch...s with Celiac Disease, Additional Data Indicates P...ORLANDO, Fla., Oct. 7 /- Alba Therape...cal studies this week at the American,College of G...ng. Data from,study CLIN 1001-004, the first Phase...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Scientific M...Call/ -- Ironwood,Pharmaceuticals, Inc. (formerly ...E: FRX ) today announced the presentation of resu...safety and efficacy in 420 patients with,irritable...s of the data,indicates that once- daily oral dosi...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5AMERIGROUP Corporation to Host Investor Day 1320 1AMERIGROUP Corporation to Host Investor Day 1320 2Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes 1317 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 2Monsanto Company Signs Share Subscription Agreement With Devgen 594 3Non Stick Gum Something to Chew On 1313 1
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish.
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees.
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish.
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish.
Medicine Products: